Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
13 août 2024 06h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
09 août 2024 16h20 HE
|
Edesa Biotech, Inc.
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
09 août 2024 07h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
08 août 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
02 juil. 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
Engitix appoints two additional international biotech industry leaders as Scientific Advisors
25 juin 2024 04h00 HE
|
Engitix Therapeutics
LONDON, June 25, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
07 juin 2024 04h30 HE
|
Boehringer Ingelheim
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH)...
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
21 mars 2024 07h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
26 févr. 2024 02h05 HE
|
Boehringer Ingelheim
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of...